[go: up one dir, main page]

BRPI0817396B8 - composição farmacêutica para tratar deficiência de vitamina b¹² - Google Patents

composição farmacêutica para tratar deficiência de vitamina b¹² Download PDF

Info

Publication number
BRPI0817396B8
BRPI0817396B8 BRPI0817396A BRPI0817396A BRPI0817396B8 BR PI0817396 B8 BRPI0817396 B8 BR PI0817396B8 BR PI0817396 A BRPI0817396 A BR PI0817396A BR PI0817396 A BRPI0817396 A BR PI0817396A BR PI0817396 B8 BRPI0817396 B8 BR PI0817396B8
Authority
BR
Brazil
Prior art keywords
deficiency
pharmaceutical composition
vitamin
treat vitamin
treating
Prior art date
Application number
BRPI0817396A
Other languages
English (en)
Inventor
Castelli Cristina
Kragie Laura
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0817396(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of BRPI0817396A2 publication Critical patent/BRPI0817396A2/pt
Publication of BRPI0817396B1 publication Critical patent/BRPI0817396B1/pt
Publication of BRPI0817396B8 publication Critical patent/BRPI0817396B8/pt
Publication of BRPI0817396C1 publication Critical patent/BRPI0817396C1/pt
Publication of BRPI0817396C8 publication Critical patent/BRPI0817396C8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composição farmacêutica para tratar deficiência de vitamina b12 método e composição para tratar deficiência de vitamina b12 em mamíferos que não tenham respondido à terapia oral de vitamina b12, inclusive preparar uma composição farmacêutica para administração oral contendo vitamina b12 e pelo menos um substrato selecionado do grupo consistindo de ácido n-[8-(2- hidroxibenzoil)amino]caprílico e seus sais farmaceuticamente aceitáveis, e então administrar a composição farmacêutica a um indivíduo para eficazmente tratar a deficiência de vitamina b12.
BRPI0817396A 2007-11-02 2008-10-31 composição farmacêutica para tratar deficiência de vitamina b¹² BRPI0817396C8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US98489807P 2007-11-02 2007-11-02
US60/984,898 2007-11-02
US2010808P 2008-01-09 2008-01-09
US61/020,108 2008-01-09
US8356608P 2008-07-25 2008-07-25
US61/083,566 2008-07-25
PCT/US2008/082064 WO2009059188A1 (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency

Publications (5)

Publication Number Publication Date
BRPI0817396A2 BRPI0817396A2 (pt) 2015-04-07
BRPI0817396B1 BRPI0817396B1 (pt) 2019-04-24
BRPI0817396B8 true BRPI0817396B8 (pt) 2020-02-04
BRPI0817396C1 BRPI0817396C1 (pt) 2020-11-17
BRPI0817396C8 BRPI0817396C8 (pt) 2021-05-25

Family

ID=40591491

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817396A BRPI0817396C8 (pt) 2007-11-02 2008-10-31 composição farmacêutica para tratar deficiência de vitamina b¹²

Country Status (18)

Country Link
US (3) US8022048B2 (pt)
EP (1) EP2215047B1 (pt)
JP (1) JP5555634B2 (pt)
KR (1) KR101344369B1 (pt)
CN (1) CN101952241B (pt)
AU (1) AU2008318423B2 (pt)
BR (1) BRPI0817396C8 (pt)
CA (1) CA2704780C (pt)
CL (1) CL2010000434A1 (pt)
CO (1) CO6280475A2 (pt)
DK (1) DK2215047T3 (pt)
ES (1) ES2443817T3 (pt)
MX (1) MX2010004716A (pt)
NZ (1) NZ585080A (pt)
PL (1) PL2215047T3 (pt)
PT (1) PT2215047E (pt)
RU (1) RU2469728C2 (pt)
WO (1) WO2009059188A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5985985B2 (ja) * 2009-08-03 2016-09-06 エミスフィアー テクノロジーズ インコーポレイテッドＥｍｉｓｐｈｅｒｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ，Ｉｎｃ． 胃腸への影響が減少した即効型ナプロキセン組成物
MX2012009914A (es) * 2010-02-24 2013-03-05 Emisphere Tech Inc Terapia oral de b12.
RS60321B1 (sr) 2010-12-16 2020-07-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline
RU2602601C2 (ru) 2011-04-12 2016-11-20 Ново Нордиск А/С Дважды ацилированные производные glp-1
US8805208B2 (en) * 2012-02-03 2014-08-12 Tyco Electronics Subsea Communications Llc System and method for polarization de-multiplexing in a coherent optical receiver
LT2827885T (lt) 2012-03-22 2018-10-10 Novo Nordisk A/S Glp-1 peptidų kompozicijos ir jų gavimas
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CN111494323B (zh) 2012-03-22 2023-03-28 诺和诺德股份有限公司 包含递送剂的组合物及其制备
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
US20170348417A1 (en) 2013-04-11 2017-12-07 Richard Louis Price Treatment of attention deficit disorders and associated symptoms
US10098848B2 (en) 2013-04-11 2018-10-16 Richard Louis Price Inositol-containing comestible units and methods of treatment using the same
US9211284B2 (en) 2013-04-11 2015-12-15 Richard Louis Price Diagnosis and treatment of P.R.I.C.E. syndrome
US20140309270A1 (en) 2013-04-11 2014-10-16 Richard Louis Price Diagnosis and treatment of a form of autistic spectrum disorder
US9603812B2 (en) 2013-04-11 2017-03-28 Richard Louis Price Treatment of autistic spectrum disorder
RU2671406C2 (ru) 2013-05-02 2018-10-31 Ново Нордиск А/С Пероральная дозированная форма соединений глюкагоноподобного пептида-1
CN109069475B (zh) 2016-04-22 2022-01-28 受体控股公司 快速作用植物类医药化合物和营养补剂
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
AU2018345812A1 (en) * 2017-10-05 2020-05-14 Spoke Sciences, Inc. Herbal compositions with improved bioavailability
US20200254041A1 (en) * 2017-10-05 2020-08-13 Receptor Holdings, Inc. Rapid onset and extended action plant-based and synthetic cannabinoid formulations
HUE063787T2 (hu) 2018-02-02 2024-01-28 Novo Nordisk As Egy GLP-1 agonistát, egy N-(8-(2-hidroxibenzoil)amino) kaprilsav sót és egy síkosítóanyagot tartalmazó szilárd készítmények
WO2020106767A1 (en) 2018-11-19 2020-05-28 Receptor Holdings, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
WO1998011900A2 (en) * 1996-09-18 1998-03-26 Sarill William J Compositions containing cobalamin and amino acids
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ES2268900T3 (es) * 1998-12-28 2007-03-16 Cobalis Corp. Tratamiento con cianocobalamina (vitamina b12) de las enfermedades alergicas.
EP1535625B1 (en) 1999-04-05 2014-01-08 Novartis AG Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
ATE554062T1 (de) 2000-03-21 2012-05-15 Emisphere Tech Inc Verfahren zur herstellung von alkylierten salicylamiden durch ein dicarboxylat- zwischenprodukt
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
ATE356631T1 (de) 2001-06-01 2007-04-15 Novartis Pharma Gmbh Orale verabreichung von parathyroidhormon und calcitonin
WO2003015822A1 (en) 2001-08-17 2003-02-27 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
TWI307279B (en) 2002-08-01 2009-03-11 Novartis Ag Oral administration of calcitonin
CN100344328C (zh) 2002-09-13 2007-10-24 锡德克斯公司 以衍生环糊精稳定化的含有水性填充组合物的胶囊
CN100579955C (zh) 2003-04-04 2010-01-13 帝斯曼知识产权资产管理有限公司 N-烷氧基草酰丙氨酸酯的制备方法
US6938439B2 (en) 2003-05-22 2005-09-06 Cool Clean Technologies, Inc. System for use of land fills and recyclable materials
JP3924616B2 (ja) 2003-06-30 2007-06-06 独立行政法人物質・材料研究機構 微小サイズの温度感知素子を用いる温度計測方法
KR20060105735A (ko) 2003-07-04 2006-10-11 니코메드 덴마크 에이피에스 경구용 부갑상선 호르몬 함유 약학 조성물
WO2005004900A1 (en) 2003-07-11 2005-01-20 Novartis Ag Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
WO2005014031A1 (en) 2003-07-23 2005-02-17 Novartis Ag Use of calcitonin in osteoarthritis
BRPI0510231A (pt) * 2004-05-06 2007-10-30 Emisphere Tech Inc composto, polimorfo cristalino, cossolvato em metanol e água, cossolvato em metanol-água, cossolvato em etanol-água, composição farmacêutica, método para administrar um agente ativo, método para preparar a forma i do snac, método para preparar a forma ii de snac, método para preparar a forma iii de snac, método para preparar a forma iv de snac, método para preparar a forma v de snac, método para preparar a forma vi de snac, composição farmacêutica e método para preparar snac amorfo
EP1773354A4 (en) * 2004-08-02 2010-05-05 Bebaas Inc COMPOSITIONS OF VITAMIN B12
WO2006124047A2 (en) 2004-08-13 2006-11-23 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
GB0427600D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
CN101296694A (zh) 2005-11-04 2008-10-29 真塔公司 药物镓组合物和方法

Also Published As

Publication number Publication date
EP2215047B1 (en) 2013-11-20
US20100016255A1 (en) 2010-01-21
EP2215047A1 (en) 2010-08-11
WO2009059188A1 (en) 2009-05-07
CO6280475A2 (es) 2011-05-20
CL2010000434A1 (es) 2011-01-28
PL2215047T3 (pl) 2014-05-30
AU2008318423A1 (en) 2009-05-07
RU2469728C2 (ru) 2012-12-20
US8288360B2 (en) 2012-10-16
EP2215047A4 (en) 2010-11-10
BRPI0817396C1 (pt) 2020-11-17
NZ585080A (en) 2012-05-25
KR101344369B1 (ko) 2013-12-24
JP2011502997A (ja) 2011-01-27
DK2215047T3 (da) 2014-02-03
ES2443817T3 (es) 2014-02-20
MX2010004716A (es) 2010-12-17
AU2008318423B2 (en) 2013-12-05
US20110293589A1 (en) 2011-12-01
US8022048B2 (en) 2011-09-20
CN101952241A (zh) 2011-01-19
US20130040910A1 (en) 2013-02-14
CA2704780A1 (en) 2009-05-07
RU2010118423A (ru) 2011-12-10
HK1146480A1 (en) 2011-06-10
BRPI0817396C8 (pt) 2021-05-25
KR20100126263A (ko) 2010-12-01
US8557792B2 (en) 2013-10-15
CA2704780C (en) 2014-06-10
JP5555634B2 (ja) 2014-07-23
BRPI0817396B1 (pt) 2019-04-24
BRPI0817396A2 (pt) 2015-04-07
CN101952241B (zh) 2014-06-11
PT2215047E (pt) 2014-01-20

Similar Documents

Publication Publication Date Title
BRPI0817396B8 (pt) composição farmacêutica para tratar deficiência de vitamina b¹²
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
BR112014008036A2 (pt) tratamento de rinite
NZ744233A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
BR112018068784A2 (pt) método para o tratamento de leucemia
CL2021003474A1 (es) Producto farmacéutico para terapia enzimática para tratamiento de homocistinuria
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
CL2021000882A1 (es) Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
BR112015012497A2 (pt) combinações farmacêuticas
NZ701274A (en) Oral b12 therapy
BR112015023368A2 (pt) método de tratamento de deficiência de vitamina b12
BR112018074434A2 (pt) composições farmacêuticas compreendendo safinamida
BR112022003687A2 (pt) Método para tratar tinnitus, composição farmacêutica para administração intranasal, e, dose unitária pulverizável de ocitocina
BRPI0517241A (pt) composição farmacêutica, e, método para preparar a mesma
BR112018067674A2 (pt) compostos derivados de carbamato, processos para preparação dos mesmos e seus usos.
AR072871A1 (es) Combinacion terapeutica que comprende un inhibidor de aurora quinasa y un agente antineoplasico, composicion farmaceutica
EA201592261A1 (ru) Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой
BR0307427A (pt) Composição farmacêutica, processo para preparar uma composição farmacêutica, método para tratar de um paciente humano ou animal que esteja sofrendo de uma condição que seja medida por cox-2, e, uso de uma composição farmacêutica
BR112018073556A2 (pt) medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato .
RU2011146671A (ru) Комбинация для профилактики и лечения эндометритов крупного рогатого скота и ее применение

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2520 DE 25/04/2019 QUANTO AO INVENTOR.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2520 DE 24/04/2019 QUANTO AO PRAZO DE VALIDADE.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2746 DE 22-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.